Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKesson
Baxter
Colorcon
McKinsey

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,255,087


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,255,087
Title:Substituted indazole derivatives active as kinase inhibitors
Abstract: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s): Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee: NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:14/534,617
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,255,087

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Try it Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Try it Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Try it Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,255,087

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07112881Jul 20, 2007

International Family Members for US Patent 9,255,087

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 067599 ⤷  Try it Free
Australia 2008280283 ⤷  Try it Free
Brazil PI0814628 ⤷  Try it Free
Canada 2693901 ⤷  Try it Free
Chile 2008002129 ⤷  Try it Free
China 101754956 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Moodys
McKesson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.